Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner
Vulnerable Plaques

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Table 1. Inflammatory and other cellular markers that have been evaluated in clinical studies to assess association with CVD clinical outcomes

Marker Studies Have Been Conducted on Population Without Known CAD* Laboratory Method Clinical Outcome Predicted
C-Reactive Protein (hs-CRP) Yes Latex-particle enhanced immunoassay MI, RV, stroke, death
Matrix Metalloproteinase9 (MMP-9) No ELISA Death
Soluble Intercellular Adhesion Molecule-1 (sICAM-1) Yes ELISA MI, stroke, death
Soluble Vascular Cellular Adhesion Mollecule-1  (sVCAM-1) No ELISA MI, stroke, death
Soluble E-selectin (sE-selectin) Yes ELISA MI, stroke, death
Interleukin-6 (IL-6) Yes ELISA MI, death
Interleukin-18 (IL-18) No ELISA MI, death
Tumor Necrosis Factor-alpha (TNF-alpha) No Quantitative enzyme immunoassay  MI, death
Soluble CD40L (immunomodulator) Yes ELISA MI, stroke, death

All of these markers have been studied in populations with known CAD.
CAD: coronary artery disease; MI: myocardial infarction; RV: revascularization; ELISA: enzyme linked immunosorbent assay.

Return to Document

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care